- Home
- Europe Circulating Tumor Cells Ctc Liquid Biopsy Market
Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-195 | No of pages: 149 | Format:
Europe circulating tumor cells (CTC) liquid biopsy market is projected to register a substantial CAGR of 24.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Stem Cell Research, Multiple Chromosome Abnormalities & Others), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories),Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerlands, Rest of Europe) - Industry Trends and Forecast -2029
Some of the major factors contributing to the growth of the Europe circulating tumor cells (CTC) liquid biopsy market are:
Increasing use of CTC liquid biopsy in cancer stem cell research
Technological advancement
Market Players:
The major companies which are dealing in the Europe circulating tumor cells (CTC) liquid biopsy market are listed below:
Eurofins Genomics ( a subsidiary of Eurofins Scientific)
MDx Health
Guardant Health
IMMUCOR
Thermo Fisher Scientific, Inc.
Menarini Silicon Biosystems
QIAGEN
Exact Sciences Corporation
Myriad Genetics, Inc.
LungLife AI, Inc.
Bio-Rad Laboratories, Inc.
Illumina, Inc.
Natera Inc.
ExoDx ( a subsidiary of Bio-Techne Corporation)
Biocept, Inc.
F. Hoffman-La Roche Ltd.
FOUNDATION MEDICINE, INC.
Lucence Health, Inc.
Inivata Ltd
Biolidics Limited
Vortex Biosciences
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET 20
1.4 LIMITATIONS 21
1.5 MARKETS COVERED 22
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 CURRENCY AND PRICING 26
2.5 DBMR TRIPOD DATA VALIDATION MODEL 27
2.6 MULTIVARIATE MODELLING 30
2.7 TECHNOLOGY LIFELINE CURVE 30
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.9 DBMR MARKET POSITION GRID 32
2.10 MARKET APPLICATION COVERAGE GRID 33
2.11 VENDOR SHARE ANALYSIS 34
2.12 SECONDARY SOURCES 35
2.13 ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 38
4.1 PESTEL ANALYSIS 39
4.2 PORTERS FIVE FORCES 40
5 REGULATIONS: EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET 42
5.1 ROLE OF FDA 42
5.2 ROLE OF CDC AND HCFA 42
6 MARKET OVERVIEW 44
6.1 DRIVERS 46
6.1.1 HIGH PREVALENCE OF CANCER 46
6.1.2 ADVANTAGES OF LIQUID BIOPSY OVER SURGICAL BIOPSY 47
6.1.3 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT EARLY DIAGNOSIS OF CANCER 48
6.1.4 RISE IN FDA APPROVAL 48
6.1.5 HEALTHCARE REIMBURSEMENT FOR LIQUID BIOPSY 49
6.2 RESTRAINTS 49
6.2.1 DOWNSIDES OF LIQUID BIOPSY 49
6.2.2 RAPID DEVELOPMENT OF ULTRASENSITIVE IMAGING TECHNOLOGIES SUCH AS MAGNETIC RESONANCE IMAGING 49
6.3 OPPORTUNITIES 50
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 50
6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 50
6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES 51
6.3.4 HUGE MARKET POTENTIAL IN DEVELOPING COUNTRIES 52
6.4 CHALLENGES 52
6.4.1 SHORTAGE OF SKILLED PERSONNEL 52
6.4.2 LACK OF ACCESSIBILITY 53
7 COVID-19 IMPACT ON EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET 54
7.1 IMPACT ON PRICE 54
7.2 IMPACT ON DEMAND 54
7.3 IMPACT ON SUPPLY 54
7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19 55
7.5 CONCLUSION: 55
8 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY 56
8.1 OVERVIEW 57
8.2 CTC DETECTION METHODS 60
8.3 CTC ENRICHMENT METHODS 60
8.4 EX VIVO POSITIVE SELECTION 61
8.5 MOLECULAR (RNA)-BASED TECHNOLOGIES 61
8.6 FUNCTIONAL IN VITRO CELL INVASION ASSAY 62
8.7 XENOTRANSPLANTATION MODELS 63
8.8 MICROCHIPS 63
8.9 SINGLE SPIRAL MICROCHANNEL 64
8.10 NEGATIVE SELECTION 65
8.11 IMMUNOCYTOCHEMICAL TECHNOLOGIES 66
9 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION 67
9.1 OVERVIEW 68
9.2 CANCER STEM CELL RESEARCH 71
9.3 MULTIPLE CHROMOSOME ABNORMALITIES 71
9.4 OTHERS 72
10 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER 73
10.1 OVERVIEW 74
10.2 RESEARCH & ACADEMIC INSTITUTES 77
10.3 REFERENCE LABORATORIES 77
10.4 HOSPITALS AND PHYSICIAN LABORATORIES 78
11 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION 79
11.1 EUROPE 80
11.1.1 GERMANY 86
11.1.2 FRANCE 88
11.1.3 U.K. 90
11.1.4 ITALY 92
11.1.5 RUSSIA 94
11.1.6 SPAIN 96
11.1.7 TURKEY 98
11.1.8 NETHERLANDS 100
11.1.9 SWITZERLAND 102
11.1.10 BELGIUM 104
11.1.11 REST OF EUROPE 106
12 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY LANDSCAPE 107
12.1 COMPANY SHARE ANALYSIS: EUROPE 107
13 SWOT ANALYSIS 108
14 COMPANY PROFILE 109
14.1 GUARDANT HEALTH 109
14.1.1 COMPANY SNAPSHOT 109
14.1.2 REVENUE ANALYSIS 109
14.1.3 COMPANY SHARE ANALYSIS 110
14.1.4 PRODUCT PORTFOLIO 110
14.1.5 RECENT DEVELOPMENTS 110
14.2 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC) 112
14.2.1 COMPANY SNAPSHOT 112
14.2.2 REVENUE ANALYSIS 112
14.2.3 COMPANY SHARE ANALYSIS 113
14.2.4 PRODUCT PORTFOLIO 113
14.2.5 RECENT DEVELOPMENTS 113
14.3 FOUNDATION MEDICINE, INC. 114
14.3.1 COMPANY SNAPSHOT 114
14.3.2 COMPANY SHARE ANALYSIS 114
14.3.3 PRODUCT PORTFOLIO 115
14.3.4 RECENT DEVELOPMENTS 115
14.4 ILLUMINA, INC. 116
14.4.1 COMPANY SNAPSHOT 116
14.4.2 REVENUE ANALYSIS 116
14.4.3 COMPANY SHARE ANALYSIS 117
14.4.4 PRODUCT PORTFOLIO 117
14.4.5 RECENT DEVELOPMENT 117
14.5 NATERA, INC. 118
14.5.1 COMPANY SNAPSHOT 118
14.5.2 REVENUE ANALYSIS 118
14.5.3 COMPANY SHARE ANALYSIS 119
14.5.4 PRODUCT PORTFOLIO 119
14.5.5 RECENT DEVELOPMENT 119
14.6 BIO-RAD LABORATORIES, INC. 120
14.6.1 COMPANY SNAPSHOT 120
14.6.2 REVENUE ANALYSIS 120
14.6.3 PRODUCT PORTFOLIO 121
14.6.4 RECENT DEVELOPMENT 121
14.7 QIAGEN 122
14.7.1 COMPANY SNAPSHOT 122
14.7.2 REVENUE ANALYSIS 122
14.7.3 PRODUCT PORTFOLIO 123
14.7.4 RECENT DEVELOPMENTS 123
14.8 THERMO FISHER SCIENTIFIC INC. 124
14.8.1 COMPANY SNAPSHOT 124
14.8.2 REVENUE ANALYSIS 124
14.8.3 PRODUCT PORTFOLIO 125
14.8.4 RECENT DEVELOPMENTS 125
14.9 BIOCEPT, INC. 126
14.9.1 COMPANY SNAPSHOT 126
14.9.2 REVENUE ANALYSIS 126
14.9.3 PRODUCT PORTFOLIO 127
14.9.4 RECENT DEVELOPMENT 127
14.10 BIOLIDICS LIMITED 128
14.10.1 COMPANY SNAPSHOT 128
14.10.2 REVENUE ANALYSIS 128
14.10.3 PRODUCT PORTFOLIO 129
14.10.4 RECENT DEVELOPMENTS 129
14.11 EXACT SCIENCES CORPORATION 130
14.11.1 COMPANY SNAPSHOT 130
14.11.2 REVENUE ANALYSIS 130
14.11.3 PRODUCT PORTFOLIO 131
14.11.4 RECENT DEVELOPMENT 131
14.12 EXODX (A SUBSIDIARY OF BIO-TECHNE CORPORATION) 132
14.12.1 COMPANY SNAPSHOT 132
14.12.2 REVENUE ANALYSIS 132
14.12.3 PRODUCT PORTFOLIO 133
14.12.4 RECENT DEVELOPMENTS 133
14.13 F. HOFFMANN-LA ROCHE LTD 134
14.13.1 COMPANY SNAPSHOT 134
14.13.2 RECENT FINANCIALS 134
14.13.3 PRODUCT PORTFOLIO 135
14.13.4 RECENT DEVELOPMENTS 135
14.14 IMMUCOR 136
14.14.1 COMPANY SNAPSHOT 136
14.14.2 PRODUCT PORTFOLIO 136
14.14.3 RECENT DEVELOPMENTS 136
14.15 INIVATA LTD 137
14.15.1 COMPANY SNAPSHOT 137
14.15.2 PRODUCT PORTFOLIO 137
14.15.3 RECENT DEVELOPMENTS 137
14.16 LUCENCE HEALTH, INC. 138
14.16.1 COMPANY SNAPSHOT 138
14.16.2 PRODUCT PORTFOLIO 138
14.16.3 RECENT DEVELOPMENTS 138
14.17 LUNGLIFE AI, INC. 139
14.17.1 COMPANY SNAPSHOT 139
14.17.2 PRODUCT PORTFOLIO 139
14.17.3 RECENT DEVELOPMENTS 139
14.18 MDXHEALTH 140
14.18.1 COMPANY SNAPSHOT 140
14.18.2 REVENUE ANALYSIS 140
14.18.3 PRODUCT PORTFOLIO 141
14.18.4 RECENT DEVELOPMENT 141
14.19 MENARINI SILICON BIOSYSTEMS 142
14.19.1 COMPANY SNAPSHOT 142
14.19.2 PRODUCT PORTFOLIO 142
14.19.3 RECENT DEVELOPMENTS 142
14.20 MYRIAD GENETICS, INC. 143
14.20.1 COMPANY SNAPSHOT 143
14.20.2 REVENUE ANALYSIS 143
14.20.3 PRODUCT PORTFOLIO 144
14.20.4 RECENT DEVELOPMENTS 144
14.21 VORTEX BIOSCIENCES 145
14.21.1 COMPANY SNAPSHOT 145
14.21.2 PRODUCT PORTFOLIO 145
14.21.3 RECENT DEVELOPMENTS 145
15 QUESTIONNAIRE 146
16 RELATED REPORTS 149
Segmentation
Short Description
Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Stem Cell Research, Multiple Chromosome Abnormalities & Others), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories),Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerlands, Rest of Europe) - Industry Trends and Forecast -2029
Market Definition:
The liquid biopsy is a non-invasive blood test which detects circulating tumor cells and tumor DNA fragments which are released into the blood from primary tumors and metastatic sites. It is a simple and precise alternative to surgical biopsy procedure, which allows surgeon to detect cancer at a very early stage.
The circulating tumor cells are a rare sub-set of cells which function as a seed of metastases. It is found in blood of patients who have developed solid tumors. The testing of circulating tumor cells allows the detection and quantification of tumor cells in the blood of cancer patients. The various types of biological phenotypes of circulating tumor cells (CTCs) exits includes stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity. Due to which, their detection needs a phase of isolation-enrichment. After that, a second phase of detection.
Market Segmentation:
Europe circulating tumor cells (CTC) liquid biopsy market is categorized into three notable segments which are based on technology, application and end user.
On the basis of technology, global circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, ex vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation methods, microchips, single spiral microchannel, negative selection and immunocytochemical technologies
On the basis of application, global circulating tumor cells (CTC) liquid biopsy market is segmented into cancer stem cell research, multiple chromosome abnormalities and others
On the basis of end user, global circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals and physician laboratories
Market Players
The major companies which are dealing in the Europe circulating tumor cells (CTC) liquid biopsy market are listed below:
Eurofins Genomics ( a subsidiary of Eurofins Scientific)
MDx Health
Guardant Health
IMMUCOR
Thermo Fisher Scientific, Inc.
Menarini Silicon Biosystems
QIAGEN
Exact Sciences Corporation
Myriad Genetics, Inc.
LungLife AI, Inc.
Bio-Rad Laboratories, Inc.
Illumina, Inc.
Natera Inc.
ExoDx ( a subsidiary of Bio-Techne Corporation)
Biocept, Inc.
F. Hoffman-La Roche Ltd.
FOUNDATION MEDICINE, INC.
Lucence Health, Inc.
Inivata Ltd
Biolidics Limited
Vortex Biosciences
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.